<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22160642</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>05</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>132</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>235-42</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-011-1906-3</ELocationID>
            <Abstract>
                <AbstractText>Animal models have demonstrated the critical role of bone marrow-derived VEGFR1(+) hematopoietic progenitor cells (HPCs) and VEGFR2(+) endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. One hundred and thirty-two patients with stages 1-4 BC were enrolled on 2 studies. Circulating CD45(+)/CD34(+)/VEGFR1(+) HPCs and CD45(dim)/CD133(+)/VEGFR2(+) EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in (1) patients without overt disease that relapsed and (2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/ml (range) increased from 645.8 (23.5-1,914) to 2,899 (1,176-37,336), P = 0.016, followed by an increase in median EPC/ml from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), P = 0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/ml increased from 1,696 (10-16,470) to 5,124 (374-77,605), P = 0.0009, and median EPC/ml increased from 26 (0-560) to 71 (0-615) prior to progression, P = 0.10. In patients with responding disease, median HPC/ml decreased from 6,147 (912-85,070) to 633 (47-18,065), P = 0.05, and EPC/ml decreased from 46 (0-197) to 23 (0-105), P = 0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Sarika</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Weill Cornell Medical College, Iris Cantor Breast Center, 425 East 61 St, 8th floor, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ward</LastName>
                    <ForeName>Maureen M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Loughlin</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boeck</LastName>
                    <ForeName>Marissa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiener</LastName>
                    <ForeName>Naomi</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuang</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cigler</LastName>
                    <ForeName>Tessa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donovan</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cobham</LastName>
                    <ForeName>Marta V</ForeName>
                    <Initials>MV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christos</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baergen</LastName>
                    <ForeName>Rebecca N</ForeName>
                    <Initials>RN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swistel</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lane</LastName>
                    <ForeName>Maureen E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mittal</LastName>
                    <ForeName>Vivek</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rafii</LastName>
                    <ForeName>Shahin</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vahdat</LastName>
                    <ForeName>Linda T</ForeName>
                    <Initials>LT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1 RR024996</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR000457</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1-RR024996</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0VUA21238F</RegistryNumber>
                <NameOfSubstance UI="D000077341">Lapatinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
                <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D040281">Vascular Endothelial Growth Factor Receptor-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P188ANX8CK</RegistryNumber>
                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RBZ1571X5H</RegistryNumber>
                <NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055018" MajorTopicYN="N">Hemangioblasts</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077341" MajorTopicYN="N">Lapatinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D040281" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22160642</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-011-1906-3</ArticleId>
            <ArticleId IdType="pmc">PMC5830135</ArticleId>
            <ArticleId IdType="mid">NIHMS484976</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2008 Dec 25;359(26):2814-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19109576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2007 Aug;18(8):1421-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17693656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jul 15;15(14):4561-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19605404</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Pathol. 2008;3:67-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18039137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2001 Nov;7(11):1194-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11689883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20610543</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1971 Nov 18;285(21):1182-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4938153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2009 Jun;100(6):1047-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19385972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Dec 8;438(7069):820-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16341007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Basic Res Cardiol. 2009 Sep;104(5):613-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19363666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Mol Med. 2009 Aug;15(8):333-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19665928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18695137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Nov 20;25(33):5287-312</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17954709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jan 1;15(1):267-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19118054</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jan 1;28(1):49-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19917841</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2009 Aug;1796(1):41-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19409450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Feb 10;28(5):780-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20048182</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2009 Jan;45(2):228-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19097774</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2008 Jan 11;319(5860):195-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18187653</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2010 Feb 15;116(4 Suppl):1027-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20127948</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Sep 14;407(6801):249-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11001068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Aug 20;23 (24):5688-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16110028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Jul 15;66(14 ):7341-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16849585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2004 Feb 1;103(3):921-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14525788</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Dec;106(3):343-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17972175</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cytometry B Clin Cytom. 2005 Mar;64(1):1-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15668988</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2006 Nov;6(11):835-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17036040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 Jan;107(1):133-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18043899</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2008 Sep 9;14(3):263-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18772115</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1996 Oct;14(10):2738-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8874335</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2006 Feb 27;94(4):524-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16450002</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
